Severe Combined Immunodeficiency
Learn what the condition is, how it may be detected early, how it is treated or managed, and which breeds or species are linked to it.
Condition snapshot
A concise guide to the condition’s pattern, detection, management and urgency.
Breeding advice appliesUse the screening guidance and veterinary or genetics advice before breeding an affected or at-risk animal.
This snapshot is a general guide, not a diagnosis or treatment plan. New, severe or worsening signs require veterinary assessment.
About the condition
Severe combined immunodeficiency, or SCID, is a fatal inherited failure of adaptive immunity in Arabian horses and their crosses. A deletion in the PRKDC gene prevents normal maturation of both B and T lymphocytes. Affected foals therefore cannot make functional antibodies or cell-mediated immune responses, even though antibodies absorbed from the mare may protect them briefly after birth.
Foals often appear normal for the first weeks. As maternal antibodies decline, usually before five months of age, they develop repeated or persistent respiratory infection, fever, diarrhoea, poor growth and enlarged lymph nodes. Pneumonia caused by adenovirus or opportunistic organisms is characteristic, but bacterial, fungal and protozoal infections can occur together. Treatment may produce a short improvement followed by relapse because the underlying immune defect remains.
SCID is autosomal recessive. A carrier is healthy but passes the variant to approximately half its offspring; mating two carriers gives each pregnancy a 25% risk of an affected foal, 50% risk of a carrier and 25% chance of a genetically clear foal. The disease itself is not contagious, although infections carried by an affected foal may threaten others.
Failure of passive transfer, prematurity and acquired infection can resemble the early presentation, but those foals possess lymphocytes and may recover with appropriate care. SCID has no practical curative treatment in horses. Prognosis for an affected foal is fatal, and prolonged antimicrobial treatment cannot create a working immune system. The effective control is DNA testing before breeding while retaining valuable carriers only in matings to genetically clear partners.
The temporary shield of colostral antibody explains the deceptively normal first weeks. As those antibodies decay, the lack of both functional humoral and cellular responses exposes the foal to organisms a normal foal controls easily. Persistent adenoviral pneumonia in an Arabian foal is especially suggestive but is not by itself genetic confirmation.
Screening & Early Detection
SCID is suspected in an Arabian or Arabian-cross foal with recurrent infection, especially adenoviral pneumonia, persistent lymphopenia and poor response to treatment. Complete blood count repeatedly shows very low lymphocyte numbers. Serum immunoglobulins become markedly reduced after maternally derived antibody wanes. IgG measured soon after birth is interpreted separately because normal colostral transfer can temporarily mask the genetic failure.
Flow cytometry or lymphocyte-function testing can demonstrate absent or profoundly reduced B- and T-cell populations, while culture, imaging and airway sampling define concurrent infections. A validated DNA test for the PRKDC deletion confirms affected, carrier or clear status from mane or tail hairs with roots or blood. Parentage and breed identity are checked when a result conflicts with clinical findings.
Breeding animals are screened before mating, not after a sick foal is produced. Both members of a proposed pair must have documented results when Arabian ancestry is possible. A negative SCID test rules out the tested deletion but does not exclude every acquired or unrelated immunodeficiency.
Treatment & Management
There is no effective replacement for the missing B- and T-cell system. Broad-spectrum antimicrobials, oxygen, fluids, nutrition and treatment directed by cultures may temporarily control individual infections, but opportunistic disease recurs and progressively compromises welfare. Plasma supplies short-lived antibodies but does not provide functioning lymphocytes or cure the genetic defect.
Once SCID is confirmed in a clinically affected foal, the veterinarian discusses prompt humane euthanasia rather than repeated invasive treatment with no prospect of recovery. Isolation and careful hygiene protect the foal from exposure during diagnostic work and protect other horses from its secondary infections. Necropsy and retained samples can confirm uncertain cases and prevent recurrence in the breeding programme.
Prevention uses verified DNA results. Clear-to-clear matings cannot produce the tested form; carrier-to-clear matings produce no affected foals but may produce carriers that must be identified before breeding. Carrier-to-carrier and carrier-to-affected matings are avoided. Carriers need no medical treatment and should not be stigmatised as ill; removing every carrier can unnecessarily narrow genetic diversity. Results are recorded against permanent identification, disclosed with sale or breeding, and used for each mating rather than relying on pedigree reputation.
